P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT

• Mazyar Shadman,
• Bhavini Srivastava,
• Sima Patel,
• Chadi Saifan,
• Monika Salkar,
• Bruno Emond,
• Priyanka Gogna,
• Ameur Manceur,
• Marie-Helene Lafeuille,
• Deborah Stephens

Affiliations

Mazyar Shadman

1 Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, WA, United States

Bhavini Srivastava

2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States

Sima Patel

2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States

Chadi Saifan

2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States

Monika Salkar

2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States

Bruno Emond

3 Analysis Group, Inc., Montréal, QC, Canada

Priyanka Gogna

3 Analysis Group, Inc., Montréal, QC, Canada

Ameur Manceur

3 Analysis Group, Inc., Montréal, QC, Canada

Marie-Helene Lafeuille

3 Analysis Group, Inc., Montréal, QC, Canada

Deborah Stephens

4 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States